| Humira (adalimumab) / AbbVie |
| Recruiting | 4 | 10 | | | Senior doctor Claus Zachariae, Abbott Denmark, Aage Bang Foundation | Urticaria | | | | |
| Ongoing | 4 | 315 | Europe | Methotrexate, Sulfasalazine, Leflunomide, Humira, N/A, Tablet, Injection, Methotrexate, Salazopyrin EN, Arava, Humira | University of Oxford, NIHR | Physical Inactivity , Poor dietary behaviour , Obesity , Overweight | | | | |
2005-001826-99: DANISH – a DANish multicenter study of new Imaging- and bio-markers for improved assessment of disease activity and progression and prediction of therapeutic outcome in Spondyloarthritis patients receiving Humira |
|
|
| Ongoing | 4 | 60 | Europe | Humira, Adalimumab, Injection | Hvidovre Hospital, Dept. of Rheumatology | Spondyloarthritis | | | | |
2012-005809-53: What is the biologic drug concentration required to maintain stable disease activity in psoriasis? |
|
|
| Ongoing | 4 | 65 | Europe | adalimumab, etanercept, Ustekinumab, Solution for injection, Humira, Enbrel, Stelera | | Psoriasis, Psoriasis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
2012-004940-31: Investigation of the molecular size distribution of hyaluronan and the effect of adalimumab treatment of psoriatic arthritis. |
|
|
| Ongoing | 4 | 30 | Europe | Injection, Humira | Dept of medical sciences, Rheumatology, AbbVie | Active psoriatic arthritis according to CASPAR, Psoriatic arthritis is a painful joint condition connected to psoriasis., Diseases [C] - Immune System Diseases [C20] | | | | |
2012-004939-23: Effet de la COmbinaison de Méthotrexate et d’Adalimumab sur la Réduction de l’Immunisation au cours de la Spondylarthrite ankylosante Effet de la COmbinaison de Méthotrexate et d’Adalimumab sur la Réduction de l’Immunisation au cours de la Spondylarthrite ankylosante |
|
|
| Ongoing | 4 | 110 | Europe | Solution for injection/infusion in pre-filled syringe, METOJECT | CHRU de TOURS, CHRU de TOURS | Cette étude portera sur une population avec une spondylarthrite ankylosante (SA) active nécessitant un traitement par adalimumab Cette étude portera sur une population avec une spondylarthrite ankylosante (SA) active nécessitant un traitement par adalimumab, Spondylarthrite ankylosante (SA) Spondylarthrite ankylosante (SA), Body processes [G] - Immune system processes [G12] | | | | |
2013-003956-18: Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis (JIA) Preventie van recidieven door risico-aangepast staken van de behandeling bij juveniele idiopathische artritis (JIA) |
|
|
| Ongoing | 4 | 325 | Europe | enbrel, humira, orencia, methotrexate, Methotrexate, EU/1/99/126/001, EU/1/03/256/001, EU/1/07/389/001, RVG 28636, RVG 104433, Injection, Infusion, Tablet, enbrel, humira, orencia, methotrexate | University Medical Center Utrecht, Interdisziplinäre Zentrum für Klinische Forschung Münster | juvenile idiopathic arthritis juveniele idiopathische artritis, juvenile (rheumatoid) arthritis jeugdreuma, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2014-001919-39: Increasing the time between adalimumab injections from two to three weeks, in patients with inflammatory bowel disease. |
|
|
| Ongoing | 4 | 80 | Europe | adalimumab, Solution for injection in pre-filled pen, Humira | Erasmus MC, Erasmus MC, fonds NutsOhra | Inflammatory bowel disease, Inflammatory bowel disease, Diseases [C] - Immune System Diseases [C20] | | | | |
2013-004406-25: Biomarkers identification of efficacy in Ankylosing Spondylitis |
|
|
| Ongoing | 4 | 70 | Europe | Humira, Solution for injection, Humira | Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Abbvie | Ankylosing Spondylitis, Ankylosing Spondylitis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2015-002284-42: The rationale for this study is to gain insight in the extent and impact of immunogenicity of TNF inhibitors in the European daily clinical practice. Furthermore, an European wide database will give insight in factors influencing immunogenicity and treatment outcome in terms of disease activit |
|
|
| Ongoing | 4 | 1650 | Europe | etanercept, adalimumab, certolizumab pegol, golimumab, infliximab, Injection, Infusion, Enbrel, Humira, Cimzia, Simponi, Remicade | READE, PFIZER | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., Not possible to specify | | | | |
| Ongoing | 4 | 200 | Europe | Humira, Injection, Adalimumab | GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives, GETAID | Crohn's disease, Crohn's disease, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
2005-001633-14: Randomised, multi-center, open-label, parallel-group study comparing adalimumab (Humira) 40 mg s.c. eow versus infliximab (Remicade) 3 mg/kg i.v. every 6. week in RA patients with unsustainable clinical response to infliximab 3 mg/kg every 8. week |
|
|
| Ongoing | 4 | 80 | Europe | Humira, Remicade, Humira, Remicade, Humira, Remicade | Hvidovre Hospital, Dept. Rheumatology | Rheumatoid arthritis | | | | |
2006-006275-21: A Randomised, Pragmatic, Open-label study of Adalimumab versus Etanercept for Rheumatoid Arthritis. |
|
|
| Ongoing | 4 | 124 | Europe | Humira, Enbrel, Humira, Enbrel | University Hospital Birmingham NHS Foundation Trust | Rheumatoid Arthritis | | | | |
2006-006632-22: Change from infliximab to adalimumab in patients with Crohn’s disease in remission on infliximab: a randomized comparative case control study. |
|
|
| Ongoing | 4 | 100 | Europe | HUMIRA, REMICADE, HUMIRA, REMICADE | University of Leuven, Division of Gastroenterology | Luminal Crohns Disease, moderate to severe, refractory to steroids and/or antimetabolitets and controlled with anti-TNF therapy | | | | |
2006-006186-16: IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic DiseaseA randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent |
|
|
| Ongoing | 4 | 535 | Europe | Methotrexate, Prednisone, Sulfasalazine, hydroxychloroquine, adalimumab, MTX, HCQ, hydroxychloroquine, Humira, hydroxychloroquine, Humira | Leiden University Medical Center, department of rheumatology | rheumatoid arthritis and undifferentiated arthritis | | | | |
2007-001190-28: Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis |
|
|
| Ongoing | 4 | 190 | Europe | Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, | King\'s College London | Rheumatoid Arthritis | | | | |
2007-000082-38: The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. |
|
|
| Ongoing | 4 | 180 | Europe | Humira® (adalimumab), 2593, Humira (adalimumab), Humira (adalimumab) | Abbott A/S Laboratories , Denmark | In early RA methotrexate and intra-articular glucocorticoid in combination with adalimumab is better than methotrexate and intra-articular glucocorticoid in achieving control of the disease as assessed by DAS28 < 3.2. | | | | |
2007-000593-24: An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis. |
|
|
| | 4 | 26 | Europe | Enbrel, Humira, Enbrel, Humira | F. Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd | Rheumatoid Arthritis. | | | | |
2008-004926-18: Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn’s disease |
|
|
| Ongoing | 4 | 100 | Europe | Humira, Remicade, Humira, Remicade | IBD Center LMU Munich | Moderate to severe Crohn’s disease | | | | |
2008-001952-32: The effect of adalimumab on immune markers in lesional psoriatic skin. |
|
|
| Ongoing | 4 | 10 | Europe | Humira, Humira | Radboud University Nijmegen Medical Centre - Department of Dermatology | Plaque psoriasis | | | | |
2009-011625-13: \"PSOGEN:Effect adalimumab op zelfbeeld en seksueel functioneren bij matige en ernstige psoriasis van de anogenitale regio; prospectief, open label pilot onderzoek\" |
|
|
| Ongoing | 4 | 20 | Europe | Humira, Humira, Humira | Abbott | Anogenital Psoriasis | | | | |
2008-005619-16: Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patients |
|
|
| Ongoing | 4 | 100 | Europe | infliximab, adalimumab, | Erasmus Medical Center | Fertility influenced by antiTNF treatment | | | | |
2008-005450-20: The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis. |
|
|
| Ongoing | 4 | 33 | Europe | Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept), Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept) | Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases | Rheumatoid arthritis | | | | |
2009-015099-86: Comparison of efficacy, safety and costs of outpatient biological treatment for psoriasis in daily clinical practice. |
|
|
| Ongoing | 4 | 200 | Europe | Humira, Enbrel, Humira, Enbrel | Radboud University Nijmegen Medical Centre | Psoriasis | | | | |
2009-017325-19: “The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work” |
|
|
| Ongoing | 4 | 160 | Europe | HUMIRA, HUMIRA | Helsingin reumakeskus | Rheumatoid arthritis | | | | |
2010-018279-99: Skin Topoproteome under Adalimumab (Humira®) Treatmentin Patients with Moderate to Severe Psoriasis |
|
|
| Ongoing | 4 | 12 | Europe | Humira 40 mg injection solution in pre-filled syringe, Humira 40 mg injection solution in pre-filled syringe | Faculty of Medicine, Otto-von-Guericke-University Magdeburg | Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA. This is the exact label indication of Humira. Conditions: In this clinical trial Humira treatment will be performed completely \"in-label\" over 16 weeks (and facultatively over an additional 4 weeks during follow-up). | | | | |
2010-020738-24: To see whether for patients with established rheumatoid arthritis that have already achieved a good response to Tumour Necrosis Factor Inhibitor (TNF inhibitor) treatment, whether the treatment be tapered to a minimum dose without affecting the control of disease activity. |
|
|
| Ongoing | 4 | 99 | Europe | Etanercept, Adalimumab, Enbrel pre-filled pen, Humira, Enbrel pre-filled syringe, Enbrel pre-filled pen, Humira, Enbrel pre-filled syringe | King\'s College London | Patients with established Rheumatoid arthritis | | | | |
2012-004482-40: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide (AR) en remisión clínica en tratamiento con terapias biológicas |
|
|
| Ongoing | 4 | 28 | Europe | Infliximab, Adalimumab, Etanercept, Certolizumab Pegol, Golimumab, Abatacept, Tocilizumab, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra | FRANCISCO J. BLANCO GARCÍA, FRANCISCO J. BLANCO GARCIA | Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies Evaluación de la utilidad clínica de un protocolo estandarizado de estrategias para la disminución de dosis en pacientes con Artritis Reumatoide en remisión clínica a tratamiento con terapias biológicas | | | | |
2013-002932-25: A randomized clinical trial: treatment of perianal fistulas in Crohn\'s disease |
|
|
| Ongoing | 4 | 111 | Europe | Infliximab, Adalimumab, Remicade, Humira, Remicade, Humira | Academic Medical Center, Academic Medical Center | Perianal fistulas in Crohn\'s Disease | | | | |
2013-004918-18: Optimising adalimumab treatment in psoriasis with concomitant methotrexate. |
|
|
| Ongoing | 4 | 100 | Europe | methotrexate, methotrexate | Academic Medical Center, Deparment of dermatology, Academic Medical Center | psoriasis | | | | |
2015-004173-32: Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. Individualiseret behandling: dosering af TNF-alfa hæmmende behandling efter serumkoncentrationsmålinger. |
|
|
| Ongoing | 4 | 500 | Europe | Solution for injection/infusion in pre-filled syringe, Solution for infusion, Enbrel, Humira, Remsima, Benepali, Remicade | Department of Clinical Biochemestry, Aarhus University Hospital, Aarhus University Hospital | Rheumatic diseases, Rheumatic diseases, Body processes [G] - Immune system processes [G12] | | | | |
2015-000943-17: Dose decrease of biologics for psoriasis Dosis afbouwen van biologics voor psoriasis |
|
|
| Ongoing | 4 | 120 | Europe | Injection, Humira (adalimumab), Enbrel (etaneracept), Stelara (ustekinumab) | Radboudumc, Zonmw | Adult Patients diagnosed psoriasis vulgaris Volwassenen gediagnosticeerd met psoriasis vulgaris, Psoriasis Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2007-005464-26: Devlopment of Heart and blood vessel problems in patients with conditions which cause long-term, widespread, inflammation in the body. |
|
|
| Ongoing | 4 | 100 | Europe | Cimzia, Remicade, Enbrel, Humira, Cimzia, Remicade, Enbrel, Humira, Cimzia | Kings College London, Guys and St Thomas\'NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust BRC | Rheumatoid Arthritis | | | | |
2016-000235-40: Stopping anti-TNF treatment in Crohn’s and Colitis patients in remission Utsättning av anti-TNF terapi hos patienter med ulcerös kolit eller Crohns sjukdom i lugn fas |
|
|
| Ongoing | 4 | 350 | Europe | Concentrate and solvent for solution for infusion, Solution for injection in pre-filled pen, Remicade, Remsima, Inflectra, Humira | Region Skåne, ALF-medel | Crohn´s disease Ulcerative colitis, Crohn´s disease Ulcerative colitis Crohns sjukdom Ulcerös kolit, Diseases [C] - Digestive System Diseases [C06] | | | | |
2016-003129-40: Remission after suspension of TNF alpha therapies in RA Remissione dopo terapia con farmaci Anti TNF in pazienti affetti da Artrite Reumatoide |
|
|
| Ongoing | 4 | 60 | Europe | HUMIRA (ADALIMUMAB), CIMZIA (Certolizumab Pegol), ENBREL (Etanercept), REMICADE (INFLIXIMAB), SIMPONI (GOLIMUMAB), [NA], [-], Solution for injection, Powder and solvent for solution for injection, Powder for solution for injection, HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER, CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL, ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ, REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV, SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AIFA - Italian Medicines Agency | RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2017-000435-13: Clinical trial to examine changes in inflammational type of active, moderate-to-severe hidradenitis suppurativa during a 6-week treatment with the approved medication Adalimumab (HUMIRA). |
|
|
| Ongoing | 4 | 15 | Europe | HUMIRA, Solution for injection in pre-filled syringe, HUMIRA | University Hospital Frankfurt for its Dermatology Department, Clinical Research, AbbVie Deutschland GmbH | Hidradenitis suppurativa is defined as a chronic inflammatory disease of the intertriginous area, including the axilla, groin and anogenital or submammary regions. The condition is characterized by inflammation, recurrent abscesses, fistulas and sinus tracts, leading to post-inflammatory contracture and accordion-like mutilating scars. Mostly this disease appears in younger patients from 15 - 45 years and is connected with a high burden of disease and decreased quality of life., Hidradenitis suppurativa is a chronic skin disease which affects the axilla and groin. This disease is common and furthermore connected with a low quality of life and other organic comorbidity., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2018-003432-72: Dose reduction and withdrawal of TNF inhibitors in patients with Psoriatic Arthritis and Axial Spondyloarthritis Afbouwen en stoppen van TNF remmers bij patiënten met Artritis Psoriatica en Axiale Spondylartritis. |
|
|
| Ongoing | 4 | 234 | Europe | Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Solution for injection/infusion, Tumor Necrosis Factor alpha (TNF-a) Inhibitors: Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab | Sint Maartenskliniek, Sint Maartenskliniek | Adults diagnosed with Psoriatic Arthritis en Axial Spondyloarthritis. Volwassenen gediagnosticeerd met artritis psoriatica en axiale spondylartritis., Psoriatic arthritis and Axial Spondyloarthritis Artritis psoriatica en axiale spondylartritis, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-002925-47: prediction of response to therapy in inflammatory bowel disease Predicción de respuesta al tratamiento en la enfermedad inflamatoria intestinal |
|
|
| Not yet recruiting | 4 | 180 | Europe | Injection, Infusion, Adalimumab, Infliximab, Golimumab, Ustekinumab, Vedolizumab | Fundación de Investigación Biomédica del Hospital Universitario de La Princesa, Instituto de Salud Carlos III | Inflammatory bowel disease Enfermedad inflamatoria intestinal, Corhn´s disease and ulcerative colitis Enfermedad de Crohn y colitis ulcerosa, Diseases [C] - Digestive System Diseases [C06] | | | | |
2018-002064-15: Patient preference model: treatment of perianal fistulas in Crohn's disease |
|
|
| Ongoing | 4 | 140 | Europe | Infliximab, Adalimumab, Powder for concentrate and solution for solution for infusion, Powder for concentrate for solution for infusion, Remicade, Humira | Academic Medical Center, Academic Medical Center | Perianal fistulas in Crohn's Disease, Perianal fistulas in Crohn's Disease, Diseases [C] - Digestive System Diseases [C06] | | | | |
2017-004588-11: Control Crohn Safe Trial: Long term outcome and tolerability of six months adalimumab as initial treatment for newly diagnosed Crohn's disease versus standard step-up treatment. Veilige controle van de ziekte van Crohn trial: Lang termijn effectiviteit en veiligheid van 6 maanden behandeling met adalimumab versus standaard step-up behandeling van nieuwe patiënten met de ziekte van Crohn. |
|
|
| Ongoing | 4 | 146 | Europe | Suspension for injection in pre-filled pen, Humira | Maastricht University Medical Centre, ZonMW | The Chronic inflammatory bowel disease Crohn's disease De chronische inflammatoire darmaandoening de ziekte van Crohn, Chronic inflammatory disease of he bowel Crohn's disease De chronische darmontsteking de ziekte van Crohn, Diseases [C] - Digestive System Diseases [C06] | | | | |
2019-000412-29: Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial (ADJUST) |
|
|
| Not yet recruiting | 4 | 118 | Europe | Humira, Solution for injection in pre-filled syringe, Humira | F.I. Proctor Foundation, University of California San Francisco, National Eye Institute, National Institutes of Health | juvenile-idiopathic arthritispaediatric uveitis, Inflammation of the joints and eyes, Diseases [C] - Eye Diseases [C11] | | | | |
2019-001754-25: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment |
|
|
| Not yet recruiting | 4 | 84 | Europe | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab, Injection, Enbrel, Benepali, Erelzi Rituximab: mabthera, Rixathon, Truxima Abatacept: Orencia Tocilizumab: Roactemra Sarilumab: Kevzara | Reade, ZonMw | rheumatoid arthritis, Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Ongoing | 4 | 60 | Europe | Abatacept, Humira, Injection, Abatacept, Humira | St George's, University of London | Rheumatoid arthritis, Rheumatoid disease, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2016-001566-28: Identifying mediators in patients with hidradenitis supportive |
|
|
| Not yet recruiting | 4 | 32 | Europe | HUMIRA, Solution for injection, HUMIRA | University College Dublin, Science Foundation Ireland | Hidradenitis Suppurativa, Rare skin disease, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Active, not recruiting | 4 | 290 | US | Etanercept, Enbrel, Infliximab, Remicade, Adalimumab, Humira, Placebo | Georgetown University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Maryland, Baltimore, Washington D.C. Veterans Affairs Medical Center, Medstar Health Research Institute, Patient-Centered Outcomes Research Institute, Arthritis and Pain Associates of PG County, Arthritis & Rheumatism Associates, P.C., Rheumatology Associates of Baltimore, L.L.C., The Arthritis Clinic of Northern Virginia, P.C., Arthritis and Rheumatic Disease Associates, P.C. | Rheumatoid Arthritis | 06/24 | 08/24 | | |
ChiCTR2000030089: A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) |
|
|
| Not yet recruiting | 4 | 60 | | Conventional treatent and adalimumab ;conventional treatment | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Shanghai Changzheng Hospital Project Fund and Drug donation from Bio-Thera Solutions, Ltd. | Novel Coronavirus Pneumonia（COVID-19） | | | | |
| Active, not recruiting | 4 | 78 | RoW | Adalimumab Injection, Thiopurine, Endoscopic balloon dilatation | St Vincent's Hospital Melbourne, Australasian Gastro Intestinal Research Foundation, AbbVie | Crohn Disease, Inflammatory Bowel Diseases, Stricture; Bowel | 09/20 | 09/21 | | |
NCT03306446: Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab |
|
|
| Active, not recruiting | 4 | 203 | Europe | Start adalimumab in monotherapy, begin humira in monotherapie in Early crohn disease patient | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | CD | 03/21 | 03/25 | | |
2019-002942-19: Nordic study of treatment strategy in inflammatory bowel disease Nordisk studie av behandlingsstrategi vid inflammatorisk tarmsjukdom |
|
|
| Ongoing | 4 | 300 | Europe, RoW | Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Film-coated tablet, Tablet, Remicade Infliximab, Humira Adalimumab, Imurel Azatioprin, Puri-nethol Merkaptopurin | Region Örebro län, VINNOVA | Crohn's disease and Ulcerative colitis, Crohn's disease and Ulcerative colitis, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT03505008: Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan |
|
|
| Active, not recruiting | 4 | 300 | Japan, RoW | Methotrexate, MTX, Adalimumab, ADA | Keio University, Eisai Co., Ltd. | Rheumatoid Arthritis | 05/21 | 06/22 | | |
2021-002211-65: EFFECT OF TOFACITINIB ON COAGULATION EFECTO DE TOFACITINIB SOBRE LA COAGULACIÓN |
|
|
| Ongoing | 4 | 60 | Europe | Injection, Infusion, Pastille, Adalimumab, Infliximab, Golimumab, Tofacitinib | Fundación Española de Gastroenterología, pfizer | ulcerative colitis colitis ulcerosa, ulcerative colitis colitis ulcerosa, Body processes [G] - Biological Phenomena [G16] | | | | |
| Terminated | 4 | 11 | US | Abatacept, Orencia, Adalimumab, Humira | Columbia University, Bristol-Myers Squibb | Rheumatoid Arthritis, Myocardial Inflammation | 09/21 | 09/21 | | |
ADDORA, NCT04194827: Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring |
|
|
| Recruiting | 4 | 267 | Europe | Adalimumab serum trough concentration, Disease activity, Adalimumab | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek | Rheumatoid Arthritis | 12/24 | 12/24 | | |
| Completed | 4 | 139 | Europe | Anti-TNF: Infliximab (Infusion), Anti-TNF discontinuation: Physiological saline solution, Anti-TNF:Adalimumab (Subcutaneus) | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis | 12/21 | 12/22 | | |
| Completed | 4 | 78 | Europe | Dose reduction to 2mg/L, Dose reduction to 5mg/L, Adalimumab | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek | Rheumatoid Arthritis | 09/23 | 09/23 | | |
ADDORA-switch, NCT04251741: Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment |
|
|
| Active, not recruiting | 4 | 86 | Europe | Adalimumab trough concentration, Usual care | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek | Rheumatoid Arthritis | 05/24 | 05/24 | | |
ChiCTR2100044045: Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases including rheumatoid arthritis, ankylosing spondylitis and psoriasis |
|
|
| Recruiting | 4 | 50 | | Adalimumab | Mianyang Hospital of Traditional Chinese Medicine; Mianyang Hospital of Traditional Chinese Medicine, None | Immune-Mediated Inflammatory Diseases | | | | |
NCT04300686: A Pilot Study in Severe Patients With Takayasu Arteritis. |
|
|
| Recruiting | 4 | 40 | RoW | Tocilizumab, IL-6R alpha antibody, Adalimumab, TNF-alpha antibody | Shanghai Zhongshan Hospital | Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment | 05/22 | 12/23 | | |
NCT05015335: The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage |
|
|
| Recruiting | 4 | 50 | RoW | Adalimumab, ADA, Methotrexate, MTX | Peking Union Medical College Hospital | Uveitis, Anterior, Adalimumab | 07/22 | 07/23 | | |
ChiCTR2000036845: A single-center, randomized, controlled study on the effect of proactive therapeutic drug monitoring on the efficacy and cost of adamumab in the treatment of Crohn's disease |
|
|
| Not yet recruiting | 4 | 120 | | In the proactive TDM group, adamumab is 160mg at week 0, 80mg at week 2, and 40mg once every two weeks from week 4 until week 8. Adalimumab serum trough concentration is going to be monitored at week 8, 16, 24, 32 and 40 after inclusion: 1.If serum trough concentration≥11.7 g/ mL, continue&# ;In the reactive TDM group, adamumab is 160mg at week 0, 80mg at week 2, and 40mg once every two weeks from week 4 until week 8. Clinical response is assesed at week 8, 16, 24, 32, and 40 after inclusion: 1.If the clinical response is achieved, continue to administer 40mg once every | Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Xinhua hospital affiliated to Shanghai jiaotong university school of medicine, Special funds | Crohn's disease | | | | |
| Active, not recruiting | 4 | 174 | Europe | Lengthening adalimumab dosing interval, Lengthening Humira dosing interval, Longer adalimumab interval, Longer Humira interval, Adalimumab dose reduction, Humira dose reduction | Radboud University Medical Center, Erasmus Medical Center | Crohn Disease in Remission, Crohn Disease | 10/22 | 10/22 | | |
| Completed | 4 | 18 | Europe | Abatacept Injection, Orencia, Adalimumab Injection, Humira | St George's, University of London | Rheumatoid Arthritis | 10/22 | 10/22 | | |
ChiCTR2100049326: A Prospective, Single-arm Clinical Study of the Efficacy and Safety of Adalimumab Incremental Therapy in Patients With Fistulizing Crohn's Disease |
|
|
| Recruiting | 4 | 60 | | Adalimumab, every 2 weeks, 40mg each time, 12 weeks of treatment ;Adalimumab, once every 2 weeks, each time 80mg, 12 weeks of treatment ;Adalimumab, every 2 weeks, 40mg each time, 12 weeks of treatment. Azathioprine, 1.5-4mg/kg/day, course of treatment for 12 weeks | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Self-financed | fistulizing Crohn's disease | | | | |
METHOBIO, NCT02829424: Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis |
|
|
| Active, not recruiting | 4 | 78 | Europe | Methotrexate, Methotrexate Placebo | Assistance Publique Hopitaux De Marseille | Psoriasis | 01/23 | 02/24 | | |
ChiCTR2100043791: Efficacy observation and safety and tolerability evaluation of adalimumab combined with isotretinoin in the treatment of severe and aggregated acne |
|
|
| Recruiting | 4 | 20 | | Adalimumab + Isotretinoin ;Isotretinoin | Dermatology Hosipital of Southern Medical University; Dermatology Hosipital of Southern Medical University, Self-financing | Severe acne and acne conglobata | | | | |
BACH, NCT04985435: Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA |
|
|
| Recruiting | 4 | 100 | Europe | Filgotinib, Jyseleca, Anti-Tumor Necrosis Factor Alpha Drug (Product), Adalimumab (Humira) Etanercept (Enbrel), 50 patients will have a Free Choice between Filgotinib and anti TNF | R.Bos, Galapagos NV, Medical Centre Leeuwarden, Leiden University Medical Center | Rheumatoid Arthritis | 03/23 | 04/23 | | |
ChiCTR2100045463: Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study |
|
|
| Recruiting | 4 | 30 | | adalimumab | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, none | intestinal Beh?et's disease | | | | |
NCT05153200: Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study. |
|
|
| Not yet recruiting | 4 | 40 | NA | Upadacitinib, Rinvoq, Adalimumab, Idacio | Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa | Rheumatoid Arthritis | 06/23 | 06/23 | | |
ChiCTR2200055876: Efficacy and safety of Iguratimod combined with adalimumab in active rheumatoid arthritis with poor response to csDMARDs |
|
|
| Recruiting | 4 | 98 | | IGU 25mg bid + adalimumab 40mg q2w | Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong Provincial Hospital Affiliated to Shandong First Medical University | Rheumatoid Arthritis | | | | |
NCT03739853: Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial |
|
|
| Recruiting | 4 | 315 | Europe | Methotrexate, Sulfasalazine, Leflunomide, Adalimumab | University of Oxford | Psoriatic Arthritis | 08/24 | 02/25 | | |
NCT05313620: Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events |
|
|
| Recruiting | 4 | 30 | Europe | Tofacitinib, Infliximab Adalimumab y Golimumab | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Ulcerative Colitis, Thromboembolism | 10/24 | 10/24 | | |
BioIBD, NCT03885713: Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease |
|
|
| Recruiting | 4 | 180 | Europe | Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis | 12/24 | 12/24 | | |
NCT05180526: Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV) |
|
|
| Active, not recruiting | 4 | 60 | RoW | QLETLI | Bio-Thera Solutions | Uveitis | 12/24 | 12/24 | | |
| Active, not recruiting | 4 | 250 | RoW | biologic DMARDs, rimicade, adalimumab | Kasr El Aini Hospital | Juvenile Idiopathic Arthritis Associated Uveitis | 12/23 | 04/24 | | |
| Active, not recruiting | 4 | 15 | Canada | Tapered doses of TNFi, etanercept 50 mg every 10 days (75% of baseline dose), 14 days (50%), 30 days (25%), adalimumab 40 mg every 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), certolizumab pegol 200 mg 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), golimumab 50 mg every 6 weeks (75%), 8 weeks (50%), 16 weeks (25%), infliximab 5 mg/kg every 8 weeks (75%), 12 weeks (50%), 16 weeks (25%), Standard dose of TNFi, etanercept 50 mg every 7 days, adalimumab 40 mg every 2 weeks, certolizumab pegol 200 mg every 2 weeks, golimumab 50 mg every 4 weeks, infliximab 5 mg/kg every 6 weeks | University Health Network, Toronto | Axial Spondyloarthritis | 07/24 | 08/24 | | |
| Recruiting | 4 | 1000 | US | Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz | Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health | Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis | 02/24 | 09/24 | | |
ChiCTR2200058839: Evaluation the efficacy and safety of reduced-dose adalimumab in Chinese patients with rheumatoid arthritis (RA): A Multicenter, prospective, parallel-group, real-world study |
|
|
| Not yet recruiting | 4 | 343 | | Treatment of adalimumab ;Treatment of adalimumab ;Treatment of adalimumab ;Treatment of adalimumab | The Second Affiliated Hospital Of Nanchang University; The Second Affiliated Hospital of Nanchang University, Biothera Solutions, formerly as Sinoasis Pharma, Ltd. | Rheumatoid arthritis | | | | |
| Recruiting | 4 | 158 | Europe | Adalimumab, Humira, standard step-up care | Maastricht University Medical Center, Maastricht University, ZonMw: The Netherlands Organisation for Health Research and Development | Crohn Disease, Inflammatory Bowel Diseases | 05/24 | 09/26 | | |
NCT03591770: Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib |
|
|
| Terminated | 4 | 15 | US | SHINGRIX, Recombinant zoster vaccine | Boston Medical Center | Inflammatory Bowel Diseases | 07/24 | 07/24 | | |
NCT05414201: A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis |
|
|
| Completed | 4 | 87 | RoW | Adalimumab, Humira | AbbVie | Non-infectious Intermediate Posterior- or Pan-uveitis | 06/24 | 06/24 | | |
FILRA, NCT06527534: Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA) |
|
|
| Recruiting | 4 | 30 | Europe | Filgotinib, Adalimumab | Universita di Verona | Rheumatoid Arthritis | 07/25 | 09/25 | | |
RA-DRUM, NCT06440629: Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial |
|
|
| Recruiting | 4 | 350 | Europe | Therapeutic drug monitoring (TDM) of adalimumab | Diakonhjemmet Hospital, Oslo University Hospital, Karolinska University Hospital, Queen Mary University of London, Medical University of Vienna, Alesund Hospital, St. Olavs Hospital, Helse Stavanger HF, Drammen sykehus, University Hospital of North Norway, Førde Hospital Trust, Hospital of Southern Norway Trust, Haukeland University Hospital, Ostfold Hospital Trust, Lillehammer Hospital for Rheumatic Diseases, Martina Hansen's Hospital, Haugesund Rheumatism Hospital, Betanien Hospital, Helgeland Hospital Trust, Nordlandssykehuset HF | Rheumatoid Arthritis | 12/27 | 12/27 | | |
VEDIAN, NCT06180382: Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. |
|
|
| Not yet recruiting | 4 | 220 | Europe | Adalimumab, Vedolizumab | Centre Hospitalier Universitaire de Saint Etienne, Takeda France | Crohn's Disease | 01/26 | 01/27 | | |
ROC-SPA, NCT03445845: Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis |
|
|
| Recruiting | 4 | 300 | Europe, RoW | Secukinumab, TNF blocker, blood specimen | Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France | Axial Spondyloarthritis | 11/24 | 11/25 | | |
ChiCTR2200067227: A randomized, multicenter, positive drug controlled clinical study protocol to evaluate the efficacy and safety of adalimumab in adults with exanthematous and severe drug eruptions |
|
|
| Not yet recruiting | 4 | 160 | | Adalimumab ;Methylprednisolone | The University of Hong Kong-Shenzhen Hospital; The University of Hong Kong-Shenzhen Hospital, None | drug eruption | | | | |
ChiCTR2300072687: A real world study of does reduction for adalimumab in Chinese patients with ankylosing spondylitis in low disease activity-a prospective multicenter cohort study |
|
|
| Not yet recruiting | 4 | 400 | | Treatment of adalimumab ;Treatment of adalimumab | First Affiliated Hospital of Chengdu Medical College, Chengdu, China; First Affiliated Hospital of Chengdu Medical College, Chengdu, China, self-funded | ankylosing spondylitis | | | | |
| Recruiting | 4 | 1300 | US | Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab | Eli Lilly and Company, Incyte Corporation | Rheumatoid Arthritis | 12/24 | 02/26 | | |
NCT05527444: The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | Secukinumab 150 mg/ml, Secukinumab, Adalimumab Ab, Adalimumab, NSAID, Thalidomide Pill | Qilu Hospital of Shandong University | Ankylosing Spondylitis | 12/24 | 12/24 | | |
ChiCTR1900027147: Efficacy and safety of adalimumab in Behcet's disease-related uveitis |
|
|
| Not yet recruiting | 4 | 30 | | Adalimumab | State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, None | Behcet's disease-related uveitis | | | | |
ChiCTR2300074783: Evaluation the efficacy and safety of adalimumab injection (SCT630) with rheumatoid arthritis (RA): A multicenter, prospective, real-world study |
|
|
| Not yet recruiting | 4 | 200 | | NA | The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, Beijing Kangwei Institute of Biological Health Sciences | Rheumatoid arthritis | | | | |
JAKAR, NCT05502731: Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis |
|
|
| Not yet recruiting | 4 | 40 | Europe | Filgotinib, Jyseleca, Adalimumab, Hyrimoz | Leiden University Medical Center, Galapagos NV | Rheumatoid Arthritis | 03/25 | 10/25 | | |
SMOOTH, NCT06390436: Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis |
|
|
| Not yet recruiting | 4 | 320 | Europe | Blood sample, Adalimumab Injection | Centre Hospitalier Universitaire de Saint Etienne, Direction Générale de l'Offre de Soins | Uveitis, Chronic Disease | 03/28 | 03/29 | | |
ChiCTR2400081637: A prospective, multicenter real-world study of Adalimumab injection (Anjiarun) in the treatment of ankylosing spondylitis |
|
|
| Recruiting | 4 | 200 | | | Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital, Beijing Kangwei Institute of Biological Health Sciences | Ankylosing spondylitis | | | | |
NCT04183608 / 2018-003490-10: A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab |
|
|
| Recruiting | 4 | 238 | Europe | Adalimumab, Calprotectin, e-Monitoring, Therapy Education | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, AbbVie | Ulcerative Colitis | 04/25 | 05/28 | | |
| Active, not recruiting | 4 | 2600 | Europe, US, RoW | Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab | Eli Lilly and Company, Incyte Corporation | Rheumatoid Arthritis | 04/25 | 02/26 | | |
NCT03816397: Adalimumab in JIA-associated Uveitis Stopping Trial |
|
|
| Active, not recruiting | 4 | 118 | Europe, US, RoW | Adalimumab, HUMIRA, Placebo | Nisha Acharya, Children's Hospital of Philadelphia, Children's Hospital Medical Center, Cincinnati, Children's Mercy Hospital Kansas City, National Eye Institute (NEI), Great Ormond Street Hospital for Children NHS Foundation Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Alder Hey Children's NHS Foundation Trust, Newcastle-upon-Tyne Hospitals NHS Trust, Sheffield Children's NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Royal Children's Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Vanderbilt University Medical Center, University of California, Davis, University of Texas at Austin, University of Miami, University Hospitals, Leicester, University of Utah, Colorado Retina Associates, Manchester University NHS Foundation Trust | Uveitis, JIA | 04/25 | 07/25 | | |
NCT05626348: The Clinical Efficacy of Immunomodulators in RA Patients |
|
|
| Recruiting | 4 | 400 | RoW | Iguratimod, IGU, T-614, Methotrexate, MTX, Adalimumab Injection, adalimu, Leflunomide, LEF, Hydroxychloroquine, HCQ | Qilu Hospital of Shandong University | Arthritis, Rheumatoid | 06/25 | 12/26 | | |
| Not yet recruiting | 4 | 270 | | Interferon Alpha-2a ;Adalimumab ;Cyclosporine | The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, Raise independently | Uveitis in Behcet's Disease | | | | |
ChiCTR2400079755: An open randomized controlled trial of Upadacitinib to improve anxiety in patients with psoriatic arthritis |
|
|
| Recruiting | 4 | 40 | | Upadacitinib (15 mg/day, qd); adalimumab (40 mg/time, once every two weeks) | Shenzhen Traditional Chinese Medicine Hospital, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine; Shenzhen Traditional Chinese Medicine Hospital, self-finance | Psoriatic arthritis anxiety disorder | | | | |
| Recruiting | 4 | 100 | RoW | Adalimumab Injection, An-jian-ning, Tofacitinib 5 MG, An-shu-zheng | Chinese SLE Treatment And Research Group | Takayasu Arteritis | 01/26 | 01/26 | | |
